The drug, PEGPH20, was designed to treat pancreatic cancer, but failed to extend the lives of patients. As a result, the drugmaker will halt all studies of the drug and instead prioritize its drug delivery technology, Enhanze, which is used by several large drugmakers.
To become profitable, the company will cut 160 jobs. It expects to be profitable by the middle of next year, Halozyme CEO Helen Torley told STAT. Halozyme’s board also authorized the company to repurchase $350 million worth of Halozyme stock over the next three years in an effort to raise the share price.
The company also told STAT it believes revenue from Enhanze will reach $1 billion by 2027. Enhanze turns medicines that have to be given intravenously over hours into shots that patients can receive in minutes. Roche and Bristol-Myers Squibb are using the technology for their cancer drugs, as are several other large drugmakers.
Read the full article here.
More articles on pharmacy:
Amgen exits neuroscience research, cuts 180 US jobs
Walgreens’ exit from health clinic business should serve as a warning to rivals
Top 10 pharmacy stories in October
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
